静脉碘对比剂对肝硬化患者CT衰减值诊断骨质疏松能力的影响
回顾性纳入208例肝硬化患者,均行腹部双能CT平扫及动脉期、静脉期增强扫描,以双能光谱CT羟基磷灰石浓度为参考标准。ROC分析显示,增强期CT衰减值诊断骨质疏松的AUC与平扫有差异(动脉期p=0.038,静脉期p=0.048),但诊断低骨量(骨质疏松或骨量减少)时无显著差异。结论:静脉对比剂会降低CT衰减值对骨质疏松的诊断能力,但不影响对低骨量的诊断。
要点
- 增强期CT衰减值诊断骨质疏松能力低于平扫,报告骨质疏松时需注意对比剂影响。
- 诊断低骨量(骨质疏松或骨量减少)时,增强与平扫CT衰减值无显著差异。
- 肝硬化患者骨质疏松评估应优先参考平扫CT衰减值。
核心结论
- 静脉碘对比剂污染会降低增强CT衰减值对肝硬化患者骨质疏松的诊断能力,但不影响对低骨量的诊断。
研究设计与样本
- 回顾性研究,纳入208例肝硬化患者(平均年龄61.25岁±9.43,范围30-82岁),均行腹部双能CT平扫及动脉期、静脉期增强扫描。
- 以双能光谱CT测得的椎体(L1-L3)羟基磷灰石浓度作为骨量参考标准,用ROC曲线评估平扫、动脉期和静脉期CT衰减值的诊断能力。
关键影像表现/征象
- CT衰减值测量于椎体(L1-L3)髓腔区域。
诊断标准与关键数值
- 平扫与动脉期CT衰减值诊断骨质疏松的AUC差异有统计学意义(p=0.038)。
- 平扫与静脉期CT衰减值诊断骨质疏松的AUC差异有统计学意义(p=0.048)。
- 平扫与动脉期CT衰减值区分低骨量(骨质疏松或骨量减少)的AUC无显著差异(p=0.773)。
- 平扫与静脉期CT衰减值区分低骨量(骨质疏松或骨量减少)的AUC无显著差异(p=0.746)。
临床应用与阅片要点
- 在肝硬化患者中利用CT衰减值评估骨质疏松时,应优先采用平扫图像,避免增强期对比剂污染导致诊断能力下降。
- 增强期CT衰减值仍可用于区分低骨量(骨质疏松或骨量减少),但诊断骨质疏松时需谨慎解读。
局限性
- 本研究为回顾性单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the influence of intravenous contrast agent on the diagnostic ability for osteoporosis using CT attenuation measurement in patients with liver cirrhosis.
METHODS: This retrospective study was approved by our institutional review board and informed consent was waived. 208 patients with liver cirrhosis (mean age, 61.25 years ± 9.43 [standard deviation]; range, 30-82 years) who underwent both unenhanced and two contrast-enhanced (arterial and venous phase) abdominal dual-energy CT examinations from January 1 to September 1, 2020, were recruited. CT attenuation values were measured in the medullary compartment of vertebral body (L1-L3) and bone mass was determined by the hydroxyapatite concentration obtained in dual-energy spectral CT and used as the reference standard. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic ability of using CT attenuation number in unenhanced, arterial, and venous phases.
RESULTS: Area under ROC curve using unenhanced CT attenuation was different from using arterial CT attenuation (p= 0.038) and venous CT attenuation (p = 0.048) to diagnosing osteoporosis. However, there was no significant difference between unenhanced CT attenuation and arterial CT attenuation (p = 0.773) and between unenhanced CT attenuation and venous CT attenuation (p = 0.746) to distinguish low bone mass (osteoporosis or osteopenia).
CONCLUSIONS: The diagnostic ability for osteoporosis using CT attenuation measurement in contrast-enhanced scans is decreased due to intravenous contrast contamination, however, which had no influence on the diagnostic ability of CT attenuation for low bone mass (osteoporosis or osteopenia).
ADVANCES IN KNOWLEDGE: The diagnostic ability of using enhanced CT attenuation values for osteoporosis decreased compared to unenhanced CT attenuation values.
引用
- Hou, Cheng, You, et al. Effect of intravenous iodinated contrast administration on diagnostic ability for osteoporosis using CT attenuation measurement in patients with liver cirrhosis. Br J Radiol. 2022. PMID: 36043473. doi:10.1259/bjr.20201251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。